Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson’s Disease

Jay S. Schneider1,*, Thomas N. Seyfried2, Hyo-S. Choi2, Sarah K. Kidd1

1 Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, United States of America, 2 Department of Biology, Boston College, Chestnut Hill, MA, United States of America

* jay.schneider@jefferson.edu

Abstract

Background
Preclinical and clinical studies have previously shown that systemic administration of GM1 ganglioside has neuroprotective and neurorestorative properties in Parkinson's disease (PD) models and in PD patients. However, the clinical development of GM1 for PD has been hampered by its animal origin (GM1 used in previous studies was extracted from bovine brains), limited bioavailability, and limited blood brain barrier penetrance following systemic administration.

Objective
To assess an alternative therapeutic approach to systemic administration of brain-derived GM1 to enhance GM1 levels in the brain via enzymatic conversion of polysialogangliosides into GM1 and to assess the neuroprotective potential of this approach.

Methods
We used sialidase from Vibrio cholerae (VCS) to convert GD1a, GD1b and GT1b gangliosides to GM1. VCS was infused by osmotic minipump into the dorsal third ventricle in mice over a 4-week period. After the first week of infusion, animals received MPTP injections (20 mg/kg, s.c., twice daily, 4 hours apart, for 5 consecutive days) and were euthanized 2 weeks after the last injection.

Results
VCS infusion resulted in the expected change in ganglioside expression with a significant increase in GM1 levels. VCS-treated animals showed significant sparing of striatal dopamine (DA) levels and substantia nigra DA neurons following MPTP administration, with the extent of sparing of DA neurons similar to that achieved with systemic GM1 administration.
Conclusion
The results suggest that enzymatic conversion of polysialogangliosides to GM1 may be a viable treatment strategy for increasing GM1 levels in the brain and exerting a neuroprotective effect on the damaged nigrostriatal DA system.

Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder primarily characterized by the loss of substantia nigra (SN) dopaminergic neurons and depletion of striatal dopamine (DA). Although there are effective treatments to lessen the signs and symptoms of PD, no therapy has yet been found to unequivocally slow the progression of the disease. Numerous preclinical studies though have shown that administration of GM1 ganglioside, a major component of plasma membrane lipid raft signaling domains, results in significant biochemical and behavioral recovery following different types of nervous system lesions [1,2], including those in animal models of PD. GM1 administration rescued damaged SN DA neurons, increased striatal DA levels and enhanced DA synthetic capacity in residual DA neurons in various animal models of PD [3–10].

Positive preclinical results with GM1 in mouse and non-human primate MPTP models of PD have translated to positive clinical data. In a 16 week double-blind placebo controlled study, a mild symptomatic effect was detected in GM1-treated subjects (vs. placebo-treated subjects) on measures of motor function [11]. A follow-up open extension of that study found that long-term (i.e., five years) use of GM1 resulted in modest symptom progression (compared to expected symptom progression) and a number of subjects had lower (improved) motor function scores after five years of GM1 use than they had at baseline prior to randomization into the original study [12]. More recently, a double-blind placebo controlled delayed start study of GM1 in PD reported that GM1 had an early-appearing symptomatic effect (similar to that previously described) and significantly slowed symptom progression over a 2 year period [13]. An imaging sub-study of the larger delayed start study examined effects of GM1 on dopamine transporter binding, as a surrogate measure of disease progression, and reported slowing of loss of binding potential (BP_{ND}) values in several striatal regions in GM1-treated subjects and in some cases, an increased BP_{ND} in some striatal regions was detected after GM1 use [14].

Although these data suggest that GM1 may have neuroprotective/neurorestorative effects in PD, its clinical development has been hampered by its animal origin (GM1 used in previous studies was extracted from bovine brains), limited bioavailability, and limited blood brain barrier penetrance following systemic administration. An alternative therapeutic approach to systemic administration of brain-derived GM1 might be to enhance endogenous levels of GM1 in vivo in the brain. One approach to enhancing GM1 levels involves the manipulation of ganglioside degradation by sialidases. The more highly expressed gangliosides in adult mammalian brain are GM1, GD1a, GD1b, GT1b, GQ1b, and to a much lesser extent GD3. GM1 is suggested to be broadly neuroprotective and based on in vitro studies. GD3, a minor ganglioside in adult mammalian brain, has been suggested to be a potential mediator of cell death [15,16], although this has not been confirmed in vivo. Sialidases hydrolyze sialic acid linkages on gangliosides and can degrade polysialogangliosides (and GD3) while increasing GM1 [17]. Dhanushkodi and McDonald [17] previously showed that brain ganglioside profiles can be altered in vivo by intraventricular infusion of Vibrio cholerae (VCS) sialidase and that this protects against excitotoxic neurodegeneration. Yang et al. [18] also showed that infusion of sialidase...
from _Clostridium perfringens_ (CPS) enhanced spinal axon outgrowth into implanted peripheral nerve grafts in a rat model of brachial plexus avulsion.

The present study assessed the extent to which administration of VCS directly to brain could increase GM1 levels and exert a neuroprotective effect similar to that observed with systemic administration of GM1 in a mouse MPTP model of PD.

**Material and Methods**

**Animals, Surgical Procedures, and MPTP Administration**

All animal procedures were approved by the Thomas Jefferson University Institutional Animal Care and Use Committee. Male C57Bl6 mice (age 7–10 weeks, Taconic Biosciences, Germantown, NY) were housed on a 12 hour light/dark cycle and had free access to food and water throughout the study. _Vibrio cholera_ (VCS) sialidase (Prozyme, Hayward, CA) was prepared in sterile artificial cerebral spinal fluid (aCSF: 150mM Na, 3mM K, 1.4mM Ca, 0.8mM Mg, 1mM P and 155mM Cl) at doses of 0.25, 0.50, or 1.0 U/mL and loaded into Alzet osmotic minipumps (Model 2004, DURECT Corp., Cupertino, CA) according to the manufacturer’s instructions. These pumps deliver their contents at a constant rate of 0.25 μl/hour for 4 weeks. Control pumps containing only vehicle (aCSF) were also prepared. Brain infusion cannulae (ALZET Brain Infusion Kit 3, DURECT Corp., Cupertino, CA) were attached to the pumps, which were assembled approximately 24 hours prior to surgical implantation and primed in sterile saline at 37°C to ensure immediate delivery of sialidase or vehicle following implantation. On the day of surgery, animals were anesthetized with ketamine/xylazine (100/10 mg/kg, i.p.) and placed into a stereotaxic head holder. The skull was exposed and a subcutaneous intrascapular pouch was created in which to place the pump. The cannula was inserted into the third ventricle using the following coordinates: -0.22mm from Bregma, 0.87mm lateral to the midline, and 2.5mm below the cortical surface [19]. Post-surgery analgesia was achieved with buprenorphine (2.5 mg/kg, i.p.).

One week after surgery, animals received administration of MPTP-HCl (20 mg/kg, s.c., twice daily, 4 hours apart, for 5 consecutive days, Sequoia Research Products LTD, Berkshire, UK) and were euthanized 2 weeks after the final MPTP injection. Pumps were retrieved to verify that the appropriate amount of fluid was administered to the animal. Additional animals (N = 16) received MPTP as described above and beginning 24 hours after the last MPTP injection, were administered GM1 ganglioside (N = 8, 30 mg/kg, i.p., Fidia Pharmaceutical Corp, Abano Terme, Italy) or saline (N = 8) once daily for 14 consecutive days. At the time of euthanasia, brains were removed quickly and the striatum contralateral to the side of infusion was dissected and frozen for later analysis. The remainder of the brain was submersion fixed in 4% paraformaldehyde for later histological processing.

**Measurement of Striatal Dopamine and Metabolite Levels**

Striatal samples were sonicated in 0.4 M perchloric acid and centrifuged at 15,000 rpm for 5 min at 4°C. The supernatant was used for high-performance liquid chromatography (HPLC) analysis of DA and metabolites using a Coulochem III LC System (Thermo/Dionex, US), as previously described [20]. Peak heights were compared with internal standard values to determine the concentration of DA and metabolites (EZchrome V3.1, Agilent Technologies, Santa Clara, CA).

**Immunohistochemistry and Stereological Cell Counting**

Fixed tissue blocks were immersed in 30% sucrose for cryoprotection and sectioned frozen on a sliding microtome (30μm section thickness). All sections through the rostro-caudal extent of
the substantia nigra pars compacta (SNc) were collected and every third section was processed for tyrosine hydroxylase (TH) immunohistochemistry, with adjacent sections stained with cresyl violet [20]. Briefly, sections were washed in PBS and endogenous peroxidase activity was quenched using peroxide/PBS containing 0.3% Triton X-100. Sections were then blocked in 5% non-fat milk, washed, and incubated overnight with primary antibody (rabbit anti TH, 1:1,000, Pel-Freez, Rogers, AR). Following additional washes, sections were incubated in biotinylated secondary antibody, avidin biotin complex (VECTASTAIN Elite ABC system, VECTOR Laboratories, Burlingame, CA) and reaction product was visualized with NovaRED (VECTOR Laboratories, Burlingame, CA). Sections were then mounted on slides, dehydrated, cleared, and coverslipped.

Slides were coded and analyzed blindly to estimate the number of TH+ and cresyl violet stained cells in the region of interest (SNc) on one side in each animal by unbiased stereological counting (StereoInvestigator, MBF Bioscience, Williston, VT), as described previously [20]. The SNc was identified and outlined at 4x magnification and cells were counted at 100x magnification. Only cells with clear cytoplasmic staining and a distinct nucleus contained within the counting frame were counted. The same counting regions from an individual animal were used for both TH and cresyl violet counts. Cell counts were only accepted with a Gundersen CE of <0.1.

Sections from the striatum were used for visualization of gangliosides by fluorescence immunohistochemistry. Sections were washed in PBS and then blocked for 1 hour at room temperature and incubated in primary antibody over night (rabbit anti-GM1 1:250 (Abcam, Cambridge, MA); mouse anti-GT1b 1:250 (EMD Millipore, Billerica, MA); mouse anti-GD1a 1:250 (Millipore, Billerica, MA); mouse anti-GD3 1:100 (Thermo Scientific, US)). Sections were then washed and incubated with biotinylated secondary antibody directed against the appropriate host (1:500) for 2 hours followed by treatment with ABC- horseradish peroxidase (HRP) reagent for 1 hour. Signal detection was enhanced by further incubation with a fluorophore-conjugated anti-HRP antibody (Alexa Fluor 488 anti-HRP 1:500, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, or DyLight 488, Vector Laboratories, Burlingame, CA).

Ganglioside Isolation, Purification and Quantification

Gangliosides were isolated and purified from lyophilized tissues using modifications of previously described procedures [21–23]. Samples were centrifuged at 2500 rpm for 20 min, and the supernatant was collected. The pellet and stirring bar were washed in 2 ml CHCl₃:CH₃OH 1:1 (v/v), centrifuged again and the second supernatant was combined with the first. The supernatant was brought up to 19.6 ml at a ratio of 30:60:8 CHCl₃:CH₃OH: dH₂O (v/v/v). Neutral lipids were separated from acidic lipids and gangliosides using DEAE Sephadex (A-25, GE Healthcare, Upsala, Sweden) column chromatography procedure previously described [24]. Gangliosides were separated from the acidic lipids using Folch partitioning, base treated, and desalted as previously described [25].

Total ganglioside content was quantified before desalting using the resorcinol assay as described previously [25]. The resorcinol assay aliquot was estimated to contain 1.0 μg ganglioside sialic acid. The resorcinol assay was not performed after desalting as the preliminary isolation using mouse brain standard of similar weight yielded a low recovery rate (30%, not shown).

Gangliosides were analyzed qualitatively by high-performance thin-layer chromatography (HPTLC) according to modifications of previously described methods [25]. Gangliosides were spotted in 7-mm bands on the plate using a TLC spotter (CAMAG Scientific, Inc., Wilmington, NC). The amount of lipid spotted per lane was estimated to be 1.5 μg assuming a 30% recovery
after desalting. The percent distribution of each band was determined using previously
described methods [26]. The total ganglioside distribution was normalized to 100%.

DA Uptake Assay
An additional set of animals received intraventricular infusion of sialidase (N = 3, VCS 0.5 U/ml)
or aCSF only (N = 4) to examine potential effects of sialidase administration on DA uptake during
the same period of time in which animals received MPTP during the main study. Thus, sialidase
was administered for 12 days, encompassing a period equivalent to the 1 week of sialidase
infusion prior to MPTP administration and the 5 day MPTP exposure period. These animals
were then euthanized to examine effects of sialidase treatment on DA transporter activity. Dopamine
uptake was estimated in whole striatal homogenates as described previously [27]. Total
uptake was measured after adding 100 μl of fresh striatal homogenate to tubes containing assay
buffer (50 mM Tris–HCl, pH 7.4; 120 mM NaCl; 5 mM KCl; 0.32 M sucrose), 100 μM pargyline
and 0.5 μM [3H]DA (specific activity = 78.0 Ci/mmol, Perkin Elmer, Waltham, MA). Nonspecific
uptake was assessed by the addition of 100 μM mazindol to the uptake assay buffer. The
reaction proceeded at 37°C for 3 min, was terminated by placing the tubes in ice, and samples
were quickly vacuum filtered onto Whatman GF/B filters using a Brandel Harvester (Brandel,
Inc., Gaithersberg, MD). Following rinses with cold assay buffer, filters were dried, placed in scintillation
vials containing 10 ml of scintillation fluid and radioactivity was quantified by liquid
scintillation spectrometry. All samples were run in duplicate and results were normalized to protein concentration.

Data Analysis
All data shown are expressed as means ± standard errors. Where appropriate a one-way analysis
of variance (ANOVA) with Bonferroni or Dunnet’s post hoc multiple comparisons post hoc
tests was used to determine statistical significance (defined as p < 0.05).

Results
Sialidase treatment partially protects against striatal dopamine depletion in MPTP-treated mice
Ganglioside biosynthetic pathways and the effects of VCS on ganglioside biosynthesis are
depicted in Fig 1. Two weeks following the last MPTP exposure, striatal DA levels in animals
that received intraventricular infusion of aCSF alone were reduced by 89.8 ± 1.3%. Infusion of
VCS for 2 weeks resulted in a dose-dependent sparing of striatal DA levels (F(3,23) = 5.36;
P = 0.0060). The 0.25U and 1.0U doses did not have a statistically significant effect on striatal
DA levels but the 0.5U dose significantly increased striatal DA levels compared to a CSF-
treated animals (t = 3.72, P < 0.01) (Fig 2, Table 1). Administration of VCS to normal animals
had no significant effects on striatal DA levels.

Infusion of VCS significantly increased striatal dihydroxyphenylacetic acid (DOPAC) levels
in MPTP-treated animals (compared to animals with aCSF infusions) only at the 0.50U dose
(t = 3.76, P < 0.01) (Fig 2, Table 1). Striatal DA turnover (DOPAC/DA ratio) was significantly
increased in animals that received MPTP and aCSF infusions (t = 5.58, P < 0.0001) (Table 1)
and was unaffected by VCS infusions in MPTP-treated animals (Table 1). Administration of
VCS to normal animals had no significant effects on striatal DOPAC levels or DOPAC/DA
ratio (Table 1).
Sialidase treatment partially protects against loss of SNc DA neurons in MPTP-treated mice

The number of TH+ cells in the SNc (counted on one side in each animal) was significantly influenced by MPTP administration and by sialidase treatment ($F(4,32) = 9.10$, $P < 0.0001$; Table 2). MPTP administration caused a $38.7 \pm 4.7\%$ loss of SNc DA neurons, compared to normal/aCSF controls ($t = 4.63$, $P < 0.001$). MPTP-treated animals that received the 0.50U dose of VCS had a significant sparing of SNc DA neurons ($9.6 \pm 4.5\%$ loss, $t = 3.37$, $P < 0.01$ vs. MPTP/aCSF) (Table 2, Fig 3), while the other doses of VCS had no significant effect on DA cell number. Similarly, the number of cresyl violet-stained cells in the SNc was significantly influenced by MPTP administration and by sialidase treatment ($F(4,26) = 15.73$, $P < 0.0001$). MPTP administration caused a $39.4 \pm 3.4\%$ loss of cresyl violet-stained neurons, compared to normal/aCSF controls ($t = 6.08$, $P < 0.001$). MPTP-treated animals that received the 0.50U dose of VCS showed a significant sparing of cresyl violet-stained neurons ($10.3 \pm 3.7\%$ loss, $t = 4.34$, $P < 0.001$ vs. MPTP/aCSF) (Fig 3).

Sialidase treatment altered the ganglioside expression profiles

VCS-treated mice showed an increase in GM1 expression and decreased expression of GT1b, GD1a, GQ1b, consistent with the expected effects of VCS on gangliosides (Fig 4). These changes in ganglioside expression were observed immunohistochemically in striatal sections.
and further observed by HPTLC, which further showed that GM2 and GM3 levels were unaffected by the treatment (Fig 5, Table 3). Immunohistochemistry data suggested a decrease in GD3 in VCS-treated animals, however, this could not be confirmed by HPTLC.

Sialidase treatment had no effect on dopamine uptake
Since sialidase administration began prior to MPTP administration, we performed DA uptake studies to assess whether administration of sialidase could have altered the uptake of DA (and thus potentially MPTP), which could potentially interfere with the mechanism responsible for the toxic effect of MPTP on DA neurons [28]. Administration of VCS (0.50U dose) had no significant effect on DA uptake (Fig 6).

Comparison of effects of GM1 and sialidase administration on MPTP-treated mice
Consistent with prior studies [7, 29], two weeks of GM1 administration had a significant sparing effect on striatal DA levels (70.8 ± 0.9% reduction vs. 90.3 ± 1.2% reduction in MPTP/saline-treated animals, \( t = 12.61, P < 0.0001 \)) (Fig 7, Table 1). DOPAC levels were also significantly affected by GM1 administration (\( t = 4.77, P = 0.0003 \) vs. MPTP/saline) and DOPAC/DA ratios were significantly decreased, compared to MPTP/saline-treated animals (\( t = 4.84, P = 0.0003 \)) (Table 1). GM1 treatment also had a significant sparing effect on the number of
Table 1. Effects of sialidase and GM1 ganglioside administration on striatal dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) levels.

| Treatment            | n  | DA (μg/g wet tissue) | DOPAC (μg/g wet tissue) | DOPAC/DA |
|----------------------|----|----------------------|-------------------------|----------|
| Normal/Saline        | 10 | 9.04 ± 0.39          | 0.88 ± 0.05             | 0.100 ± 0.008 |
| Normal/GM1           | 8  | 8.27 ± 0.32          | 0.76 ± 0.03             | 0.092 ± 0.004 |
| MPTP/Saline          | 8  | 0.87 ± 0.11          | 0.21 ± 0.02             | 0.252 ± 0.022 |
| MPTP/GM1             | 8  | 2.64 ± 0.08          | 0.35 ± 0.02             | 0.134 ± 0.010 |
| Normal/aCSF          | 7  | 9.28 ± 0.55          | 0.81 ± 0.03             | 0.093 ± 0.004 |
| Normal/0.25U/ml VCS  | 8  | 10.05 ± 0.56         | 0.88 ± 0.06             | 0.088 ± 0.005 |
| Normal/0.50U/ml VCS  | 7  | 9.37 ± 0.47          | 0.92 ± 0.13             | 0.096 ± 0.011 |
| Normal/1.0U/ml VCS   | 7  | 9.95 ± 0.54          | 0.99 ± 0.18             | 0.100 ± 0.150 |
| MPTP/aCSF            | 9  | 0.77 ± 0.09          | 0.15 ± 0.01             | 0.173 ± 0.010 |
| MPTP/0.25U/ml VCS    | 8  | 0.88 ± 0.10          | 0.15 ± 0.01             | 0.180 ± 0.013 |
| MPTP/0.50U/ml VCS    | 6  | 1.38 ± 0.10          | 0.22 ± 0.02             | 0.163 ± 0.013 |
| MPTP/1.0U/ml VCS     | 5  | 1.09 ± 0.16          | 0.16 ± 0.03             | 0.142 ± 0.006 |

a P < 0.0001 vs. Normal/Saline
b P < 0.001 vs. MPTP/Saline
c P < 0.001 vs. Normal/aCSF
d P < 0.01 vs. MPTP/aCSF
e P < 0.05 vs. MPTP/Saline
f P < 0.0001 vs. Normal/aCSF
g P < 0.05 vs. MPTP/aCSF.

Data shown are mean ± SEM.
doi:10.1371/journal.pone.0143351.t001

TH+ cells (41.8 ± 5.7% loss in MPTP saline animals vs. 4.6 ± 4.8% loss in MPTP/GM1 animals, t = 5.032, P = 0.0002) and the number of cresyl violet-stained cells in the SNc (35.4 ± 2.1% loss in MPTP/saline animals vs. 9.9 ± 3.5% loss in MPTP/GM1 animals, t = 6.04, P < 0.0001) (Fig 7).

In comparison with GM1 administration, VCS administration had a smaller effect on striatal DA levels in MPTP-treated animals than did GM1 administration however, at the 0.50U

Table 2. Effects of sialidase and GM1 ganglioside administration on unilateral substantia nigra pars compacta dopamine neuron cell counts.

| Treatment            | n  | TH+ Neurons |
|----------------------|----|-------------|
| aCSF/Saline          | 8  | 4,092 ± 140.9 |
| aCSF/MPTP            | 7  | 2,510 ± 192.1 |
| 0.25U/ml VCS/MPTP   | 8  | 2,666 ± 341.5 |
| 0.50U/ml VCS/MPTP   | 7  | 3,699 ± 184.7 |
| 1.0U/ml VCS/MPTP    | 7  | 2,630 ± 280  |
| Normal/Saline       | 7  | 4,261 ± 182.2 |
| MPTP/Saline         | 7  | 2,479 ± 242.0 |
| MPTP/GM1            | 8  | 4,063 ± 205.0 |

a P < 0.001 vs. aCSF/Saline
b P < 0.01 vs aCSF-MPTP
c P < 0.0001 vs. Normal/Saline
d P < 0.0001 vs. MPTP/Saline.
Data shown are mean ± SEM.
doi:10.1371/journal.pone.0143351.t002
dose, sparing effects on the number of TH⁺ and cresyl violet-stained cells were similar to that observed with GM1 (Fig 8).

**Discussion**

Administration of GM1 ganglioside has had beneficial effects on behavior, striatal DA levels and SNc DA neurons in animals with experimentally-induced Parkinsonism (ex., [3–10]. In PD patients, long-term GM1 use has shown potential for disease modification [12–14]. Although the precise mechanisms underlying the clinical benefit from systemic GM1 administration are currently unknown and are likely multi-factorial, GM1 levels appear to be decreased in the brain of patients with PD [30, 31] and systemic administration of GM1 (i.e, GM1 replacement therapy) may deliver a sufficient amount of GM1 to SN DA neurons to stabilize them and promote their survival. Recent work by Hadaczek et al. [31] suggest that GM1 may regulate glial cell-derived neurotrophic factor (GDNF) signaling, a function necessary for maintaining the health of DAergic neurons. GM1 was shown to be required for assembly of the GDNF receptor and effective GDNF signaling was dependent on an adequate level of GM1 [31]. It possible that such an activity of GM1 could contribute to its neuroprotective potential. However, given the challenges associated with sourcing GM1 and delivering it the brain, we sought an alternative therapeutic approach to increasing GM1 levels in the brain. Taking advantage of the known biochemistry of ganglioside biosynthesis and degradation, we explored
the potential for enhancing GM1 levels in the brain by intracranial administration of VCS sialidase, which cleaves the glycosidic linkages between terminal sialic acids of complex gangliotetraose gangliosides GD1a, GD1b, and GT1b, and GQ1b to yield increased levels of GM1[17] and the potential for this enzyme to exert a neuroprotective effect in the MPTP mouse model of Parkinsonism.

Intracranial administration of VCS resulted in the expected changes in a- and b-series gangliosides as described previously by Dhanushkodi et al. [17]. That is, GM1 levels significantly increased while GD1a, GT1b, and GQ1b levels decreased. It is interesting that the percent distribution of GD1b was elevated rather than decreased relative to the other gangliosides. GD1b could be located in a compartment not readily accessible to VCS, which could have artificially magnified the content of GD1b. For example, GD1b is present in myelin and it is possible that with a loss of cell bodies or terminals, the appearance of gangliosides enriched in white matter could be magnified. However, it is most likely that the increase in GM1 levels were responsible for the partial sparing of nigrostriatal DA neurons following MPTP administration, as the DA neuron-sparing effect from VCS administration was similar to that obtained with systemic GM1 administration. Considering the similar efficacy of VCS and GM1 administration on SNC DA neurons, the finding that VCS administration did not have as robust an effect on striatal...
DA levels as did GM1 administration was surprising and the reasons for this are not entirely clear. It is possible that the decrease in GD1a and several b-series gangliosides may have affected dopamine synthesis. Although there are few studies of the effects of gangliosides other than GM1 on animal models of PD, one study did show that stereotaxic injection of GD1a into the striatum of MPTP-treated mice significantly increased striatal DA levels [32]. It is possible that both GM1 and GD1a contribute to the recovery of DA synthesis in MPTP-lesioned animals; in the current study, there was a significant decrease in GD1a in VCS-treated animals. However, considering the degree of sparing of SNc DA neurons, it is likely that striatal DA would recover and with longer post-MPTP survival times we would expect to see recovery of striatal DA levels at least to the extent seen with GM1 administration.

The neuroprotective effects associated with VCS administration were likely due to the enhancement of endogenous GM1 levels and not alterations in the kinetics of MPTP-mediated toxicity. MPP⁺ toxicity is dependent upon the uptake of MPTP into DAergic neurons via the dopamine transporter (DAT) [33] and DAT is a glycoprotein containing N-linked sugars and

Table 3. Effects of sialidase administration on brain gangliosides.

| Treatment | Region | GM3  | GM2  | GM1  | GD1a | GD1b | GT1b | GQ1b |
|-----------|--------|------|------|------|------|------|------|------|
| Control   | CP     | 1.5 ± 0.3 | 1.5 ± 0.1 | 12.3 ± 0.8 | 35.9 ± 1.2 | 10.0 ± 0.7 | 22.0 ± 0.2 | 7.1 ± 0.2 |
| VCS       | CP     | 1.4 ± 0.2 | 1.8 ± 0.1 | 32.5 ± 0.4ₚ | 23.6 ± 0.6ₚ | 15.1 ± 0.4ₚ | 13.8 ± 0.2ₚ | 4.6 ± 0.9* |
| Control   | HIIPP  | 1.9 ± 0.2 | 1.2 ± 0.2 | 10.3 ± 0.7 | 29.7 ± 1.2 | 11.2 ± 0.8 | 22.6 ± 0.5 | 10.8 ± 0.6 |
| VCS       | HIIPP  | 1.7 ± 0.1 | 1.2 ± 0.1 | 21.1 ± 0.2ₚ | 21.9 ± 0.4ₚ | 17.2 ± 0.7ₚ | 18.7 ± 1.3+ | 8.8 ± 0.4 |

*P < 0.0001 vs. Control
*P < 0.05 vs. Control
*P < 0.01 vs. Control

doi:10.1371/journal.pone.0143351.t003
Fig 6. Striatal uptake of tritiated dopamine (3H-DA). Striatal homogenates were incubated with 3H-DA in the presence (non-specific) or absence (total) of the dopamine uptake inhibitor mazindol. Mazindol effectively blocked DA uptake; sialidase treatment did not. Specific uptake of DA was not altered by Vibrio cholerae (VCS) sialidase (0.5U/mL, infused by osmotic minipump for 12 days).

doi:10.1371/journal.pone.0143351.g006

Fig 7. Effects of systemic administration of GM1 ganglioside (30 mg/kg, i.p.) on striatal dopamine levels and substantia nigra dopamine neurons. GM1 was administered daily for 14 days beginning 24 hours after the last MPTP injection. GM1 administration significantly increased striatal dopamine levels (A., ***p<0.001 vs. MPTP) and resulted in a significant sparing of both tyrosine hydroxylase immunopositive (B., ^p<0.0001 vs. MPTP) and Nissl-stained (C., ***p<0.001 vs. MPTP) cells in the substantia nigra pars compacta.

doi:10.1371/journal.pone.0143351.g007
sialic acids [34, 35]. It was previously suggested that DA uptake was inhibited in a non-competitive way by treatment of synaptosomes with high concentrations of neuraminidase (sialidase) from Vibrio cholerae [36]. However, our results suggest that the function of DAT was not altered by VCS administration. Dopamine uptake rates in striatal homogenates were not altered by sialidase treatment and thus it is unlikely that sialidase administration affected the toxicokinetics of MPTP. There are no reported or predicted effects of sialidase treatment on monoamine oxidase B activity and thus, VCS-related inhibition of monoamine oxidase B activity and inhibition of conversion of MPTP to MPP⁺ is an unlikely mechanism contributing to our results.

While the current study employed a pre-treatment paradigm in order to have GM1 levels increased prior to MPTP exposure, we believe that up-regulation of endogenous GM1 levels may represent an effective alternative to systemic GM1 treatment. As stated previously, PD is a progressive neurodegenerative disorder and SNc DA neurons continue to become damaged and die throughout the course of the disease. Therefore, even with the currently used pre-treatment paradigm, one could predict that enhancing GM1 levels beginning at any point in the disease process could have potentially positive effects for patients with PD. Further studies are needed to examine the long-term effects of sialidase treatment as well as alternative strategies to increase GM1 in vivo in order to translate these findings into a viable treatment for PD patients.

Conclusions

In summary, the present study found that the intraventricular administration of VCS mediated enzymatic conversion of polysialogangliosides into GM1, and in a mouse PD model, this had neuroprotective efficacy and spared SNc DA neurons to a similar extent as did systemic administration of GM1 ganglioside. Overall, the results suggest that enzymatic conversion of polysialogangliosides to GM1 in vivo may be a viable alternative treatment strategy for increasing GM1 levels in the brain and exerting a neuroprotective/neurorestorative effect on the damaged nigrostriatal DA system.
Acknowledgments

This research was supported by the Michael J. Fox Foundation.

Author Contributions

Conceived and designed the experiments: JSS. Performed the experiments: JSS TNS H-SC SKK. Analyzed the data: JSS TNS H-SC SKK. Wrote the paper: JSS TNS H-SC SKK.

References

1. Jonsson G, Gorio A, Hallman H, Janigro D, Kojima H, Luthman J, et al. (1984) Effects of GM1 ganglioside on developing and mature serotonin and noradrenaline neurons lesioned by selective neurotoxins. Journal of neuroscience research 12: 459–475. PMID:6438349
2. Oderfeld-Nowak B, Skup M, Ulas J, Jezierska M, Gradkowska M, Zaremba M (1984) Effect of GM1 ganglioside treatment on postlesion responses of cholinergic enzymes in rat hippocampus after various partial deafferentations. Journal of neuroscience research 12: 409–420. PMID:6502758
3. Hadjiconstantinou M, Rossetti ZL, Paxton RC, Neff NH (1986) Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP. Neuropharmacology 25: 1075–1077. PMID:3490632
4. Schneider JS, Yuwiler A (1989) GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced parkinsonism. Experimental neurology 105: 177–183. PMID:2568945
5. Tilson HA, Harry GJ, Nanny K, Hudson PM, Hong JS (1988) Ganglioside interactions with the dopaminergic system of rats. Journal of neuroscience research 19: 88–93. PMID:3125345
6. Schneider JS, Pope A, Simpson K, Taggart J, Smith MG, DiStefano L (1992) Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science 256: 843–846. PMID:1350379
7. Schneider JS, Kean A, DiStefano L (1995) GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. Journal of neuroscience research 42: 117–123. PMID:8531220
8. Pope-Coleman A, Schneider JS (1998) Effects of Chronic GM1 Ganglioside Treatment on Cognitive and Motor Deficits in a Slowly Progressing Model of Parkinsonism in Non-Human Primates. Restorative neurology and neuroscience 12: 255–266. PMID:12671298
9. Pope-Coleman A, Tinker JP, Schneider JS (2000) Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys. Synapse 36: 120–128. PMID:10767059
10. Herrero MT, Perez-Otano I, Oset C, Kastner A, Hirsch EC, Agid Y, et al. (1993) GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys. Neuroscience 56: 965–972. PMID:7904332
11. Schneider JS, Roeltgen DP, Mancall EL, Chapas-Grilly J, Rothblat DS, Tatarian GT (1998) Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study. Neurology 50: 1630–1636. PMID:9633704
12. Schneider JS, Sendek S, Daskalakis C, Cambi F (2010) GM1 ganglioside in Parkinson's disease: Results of a five year open study. Journal of the neurological sciences 292: 45–51. doi: 10.1016/j.jns.2010.02.009 PMID:20206941
13. Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du W (2013) A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. Journal of the neurological sciences 324: 140–148. doi: 10.1016/j.jns.2012.10.024 PMID:23199590
14. Schneider JS, Cambi F, Gollomp SM, Kuwabara H, Brasic JR, Leiby B, et al. (2015) GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding. Journal of the neurological sciences.
15. De Maria R, Lenti L, Malisan F, d'Agostino F, Tomassini B, Zeuner A, et al. (1997) Requirement for GD3 ganglioside in CD86- and ceramide-induced apoptosis. Science 277: 1652–1655. PMID:9287716
16. Malisan F, Testi R (2005) The ganglioside GD3 as the Greek goddess Hecate: several faces turned towards as many directions. IUBMB life 57: 477–482. PMID:16081368
17. Dhanushkodi A, McDonald MP (2011) Intracranial V. cholerae sialidase protects against excitotoxic neurodegeneration. PloS one 6: e29285. doi: 10.1371/journal.pone.0029285 PMID:22195039
18. Yang LJ, Lorenzini I, Vajn K, Mountney A, Schramm LP, Schnaar RL (2006) Sialidase enhances spinal axon outgrowth in vivo. Proceedings of the National Academy of Sciences of the United States of America 103: 11057–11062. PMID: 16847268
19. Paxinos G FK (2001) The mouse brain in stereotaxic coordinates, 2nd edn. San Diego: Elsevier Academic Press.
20. Kidd SK, Schneider JS (2011) Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 194: 189–194. doi: 10.1016/j.neuroscience.2011.08.010 PMID: 21846494
21. Hauser EC, Kasperzyk JL, d’Azzo A, Seyfried TN (2004) Inheritance of lysosomal acid beta-galactosidase activity and gangliosides in crosses of DBA/2J and knockout mice. Biochemical genetics 42: 241–257. PMID: 15487588
22. Seyfried TN, Glaser GH, Yu RK (1978) Cerebral, cerebellar, and brain stem gangliosides in mice susceptible to audiogenic seizures. Journal of neurochemistry 31: 21–27. PMID: 671019
23. Kasperzyk JL, El-Abbadi MM, Hauser EC, D’Azzo A, Platt FM, Seyfried TN (2004) N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. Journal of neurochemistry 89: 645–653. PMID: 15086521
24. Denny CA, Kasperzyk JL, Gorham KN, Bronson RT, Seyfried TN (2006) Influence of caloric restriction on motor behavior, longevity, and brain lipid composition in Sandhoff disease mice. Journal of neuroscience research 83: 1028–1038. PMID: 16521125
25. Arthur JR, Wilson MW, Larsen SD, Rockwell HE, Shayman JA, Seyfried TN (2013) Ethylendioxy-PiP2 oxalate reduces ganglioside storage in juvenile Sandhoff disease mice. Neurochemical research 38: 866–875. doi: 10.1007/s11064-013-0992-5 PMID: 23417430
26. Hauser EC, Kasperzyk JL, d’Azzo A, Seyfried TN (2004) Inheritance of lysosomal acid beta-galactosidase activity and gangliosides in crosses of DBA/2J and knockout mice. Biochem Genet 42: 241–257. PMID: 15487588
27. Lau YS (2003) Measurement of dopamine uptake in neuronal cells and tissues. Methods in molecular medicine 79: 465–471. PMID: 12506717
28. Pileblad E, Carlsson A (1985) Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain. Neuropharmacology 24: 689–692. PMID: 3875057
29. Anderson DW, Bradbury KA, Schneider JS (2006) Neuroprotection in Parkinson models varies with toxin administration protocol. The European journal of neuroscience 24: 3174–3182. PMID: 17156378
30. Wu G, Lu ZH, Kulkarni N, Ledeen RW (2012) Deficiency of ganglioside GM1 correlates with Parkinson’s disease in mice and humans. Journal of neuroscience research 90: 1997–2008. doi: 10.1002/jnr.23090 PMID: 22714832
31. Hadaczek P, Wu G, Sharma N, Ciesielska A, Bankiewicz K, Davidow AL, et al. (2015) GDNF signaling implemented by GM1 ganglioside; failure in Parkinson’s disease and GM1-deficient murine model. Experimental neurology 263: 177–189. doi: 10.1016/j.expneurol.2014.10.010 PMID: 25448159
32. Date I, Notter MF, Felten SY, Felten DL (1985) Stereotaxic injection of GD1α ganglioside induces limited recovery of striatal dopaminergic system in MPTP-treated aging mice. Journal of neuroscience research 28: 525–530. PMID: 1678435
33. Chiba K, Trevor AJ, Castagnoli N Jr. (1985) Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochemical and biophysical research communications 128: 1228–1232. PMID: 3873939
34. Grigoriadis DE, Wilson AA, Lew R, Sharkey JS, Kuhar MJ (1989) Dopamine transport sites selectively labeled by a novel photoaffinity probe: 125I-DEEP. The Journal of neuroscience: the official journal of the Society for Neuroscience 9: 2664–2670.
35. Lew R, Grigoriadis D, Wilson A, Boja JW, Simantov R, Kuhar MJ (1991) Dopamine transporter: deglycosylation with exo- and endoglycosidases. Brain research 539: 239–246. PMID: 20546000
36. Zaleska MM, Erecinska M (1987) Involvement of sialic acid in high-affinity uptake of dopamine by synaptosomes from rat brain. Neuroscience letters 82: 107–112. PMID: 3696480